Pro-Dex (NASDAQ:PDEX) Releases Earnings Results, Beats Expectations By $0.11 EPS

Pro-Dex (NASDAQ:PDEX) released its quarterly earnings data on Thursday. The medical instruments supplier reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.11, Yahoo Finance reports. The company had revenue of $15.03 million during the quarter. Pro-Dex had a net margin of 4.13% and a return on equity of 6.50%.

Pro-Dex Price Performance

Shares of NASDAQ PDEX opened at $23.28 on Friday. The stock’s 50-day simple moving average is $19.73 and its two-hundred day simple moving average is $18.85. Pro-Dex has a twelve month low of $14.51 and a twelve month high of $24.74. The firm has a market capitalization of $79.62 million, a P/E ratio of 40.14 and a beta of 0.38. The company has a quick ratio of 2.08, a current ratio of 3.45 and a debt-to-equity ratio of 0.25.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday.

Insider Activity

In other news, Director Angelita Rebamontan Domingo sold 2,585 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $18.30, for a total transaction of $47,305.50. Following the completion of the transaction, the director now owns 8,191 shares of the company’s stock, valued at $149,895.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 42.60% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.